Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties

Diabetologia

Volumn 56, Issue 8, 2013, Pages 1802-1812

  Weidner, C ^a,b   Wowro, S J ^a   Freiwald, A ^a   Kawamoto, K ^c   Witzke, A ^a,b   Kliem, M ^a   Siems, K ^d   Muller Kuhrt L ^d   Schroeder, F C ^c   Sauer, S ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c United States Department of Agriculture Agricultural Research Service and Boyce Thompson Institute for Plant Research   (United States)

^d ANALYTICON DISCOVERY GMBH   (Germany)

Author keywords

Diabetes; Insulin resistance; Metabolic syndrome; Natural product; Nutraceutical; Obesity; Peroxisome proliferator activated receptor

Indexed keywords

AMORFRUTIN B; GLUCOSE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BONE DEVELOPMENT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FLUID RETENTION; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; LIQUID CHROMATOGRAPHY; LIVER PROTECTION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOBLAST; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TRANSCRIPTION INITIATION; TREATMENT DURATION; WEIGHT GAIN;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; PPAR GAMMA; SALICYLATES;

EID: 84879957850     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2920-2     Document Type: Article

References (21)

1. Smyth S, Heron A (2006) Diabetes and obesity: the twin epidemics. Nat Med 12:75-80
2. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846
3. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Ann Rev Med 53:409-435
4. (2010) Regulators restrict Avandia in the US and suspend it in the EU. Nat Rev Drug Discov 9:828-829
5. Rosen CJ (2010) Revisiting the rosiglitazone story - lessons learned. N Engl J Med 363:803-806
6. Argmann CA, Cock TA, Auwerx J (2005) Peroxisome proliferator-activated receptor gamma: the more the merrier? Eur J Clin Investig 35:82-92, discussion 80
7. Cock TA, Houten SM, Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 5:142-147
8. Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964
9. Pourcet B, Fruchart JC, Staels B, Glineur C (2006) Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 11:379-401
10. Weidner C, de Groot JC, Prasad A et al (2012) Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci USA 109:7257-7262
11. de Groot JC, Weidner C, Krausze J, et al. (2013) Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor gamma. J Med Chem. 56:1535-1543
12. Masuzaki H, Paterson J, Shinyama H et al (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
13. Cadoudal T, Distel E, Durant S et al (2008) Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue. Diabetes 57:2272-2279
14. Tang Y, Osawa H, Onuma H, Nishimiya T, Ochi M, Makino H (1999) Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 48:1830-1835
15. Muise ES, Azzolina B, Kuo DW et al (2008) Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 74:403-412
16. Choi JH, Banks AS, Estall JL et al (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451-456
17. Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S (2007) Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med 24:94-97
18. Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415-445
19. Tschop MH, Speakman JR, Arch JR et al (2012) A guide to analysis of mouse energy metabolism. Nat Methods 9:57-63
20. Qiang L, Accili D (2012) FGF21 and the second coming of PPARgamma. Cell 148:397-398
21. Dutchak PA, Katafuchi T, Bookout AL et al (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567